Pythia Biotech
Pythia Biotech is a company focused on providing innovative in vitro drug testing platforms, leading the revolution in drug development. They develop organ-on-a-chip systems that simulate human physiological environments for more accurate drug testing, aiming to improve research efficiency and support personalized medicine. Recognized for their innovation, they have received multiple awards including the 21st National Innovation Award and recognition at international exhibitions. Their advanced microphysiological systems, such as tumor microenvironment chips and liver chips, are designed to accelerate drug discovery and personalized treatment.
Industries
Nr. of Employees
small (1-50)
Pythia Biotech
115 Taipei City, Nangang District, Research Institute Road, Section 1, Lane 130, No. 99, National Biotechnology Research Park, Building C, C311
Products
Tumor microenvironment chip (lung tumor model)
Microphysiological device designed to recreate lung tumor microenvironments for studying tumor–immune interactions and evaluating anticancer regimens in vitro.
Liver microphysiological chip
Engineered liver chip that emulates hepatic physiology and gradient environments to support drug metabolism, secretion, and hepatotoxicity assessment.
Tumor microenvironment chip (lung tumor model)
Microphysiological device designed to recreate lung tumor microenvironments for studying tumor–immune interactions and evaluating anticancer regimens in vitro.
Liver microphysiological chip
Engineered liver chip that emulates hepatic physiology and gradient environments to support drug metabolism, secretion, and hepatotoxicity assessment.
Services
Design and build customized organ-on-chip devices and establish cell culture and microenvironment conditions; services provided to academic and industry clients.
Conduct compound screening and toxicity/efficacy evaluations using organ-chip systems as alternatives or complements to 2D cultures and animal testing.
Create patient-specific multi-tissue microphysiological models from small clinical specimens (tumor and immune cells) to screen candidate therapies and support translational decision-making.
Provide technical demonstrations, consultations, and support to prospective users to explain capabilities and arrange hands-on evaluations of organ-chip platforms.
Design and build customized organ-on-chip devices and establish cell culture and microenvironment conditions; services provided to academic and industry clients.
Conduct compound screening and toxicity/efficacy evaluations using organ-chip systems as alternatives or complements to 2D cultures and animal testing.
Create patient-specific multi-tissue microphysiological models from small clinical specimens (tumor and immune cells) to screen candidate therapies and support translational decision-making.
Provide technical demonstrations, consultations, and support to prospective users to explain capabilities and arrange hands-on evaluations of organ-chip platforms.
Expertise Areas
- Organ-on-chip platforms
- Tumor microenvironment modeling
- Liver microphysiological models
- Microfluidics and microphysiological integration
Key Technologies
- Microfluidics
- Hydrogel photopolymerization
- Optofluidic thin-film lithography
- Dielectrophoresis-based cell patterning
News & Updates
2024 Asia Biotechnology Exhibition BIO Asia TAIWAN
Participation in the 2024 BIO Asia TAIWAN event to showcase innovations.
2024 National Innovation Award - Startup (Biopharmaceuticals and Precision Medicine)
Recognition for innovative work in biopharmaceuticals and precision medicine.
2024 Second National Innovation Award - Startup Enterprise
Honored as a startup enterprise at the national level.
2024 21st National Innovation Award - Startup (Biopharmaceuticals and Precision Medicine)
Received the 21st National Innovation Award for achievements in biotech and personalized medicine.
Merck Collaboration on Bionic Lung Cancer Chip
Partnership with Merck to develop bionic lung cancer chips for personalized treatment.
Pythia Biotech's Lung Cancer Bionic Chip Mass Production
Advancement towards mass production of lung cancer chips to accelerate personalized medicine.
2024 Asia Biotechnology Exhibition BIO Asia TAIWAN
Participation in the 2024 BIO Asia TAIWAN event to showcase innovations.
2024 National Innovation Award - Startup (Biopharmaceuticals and Precision Medicine)
Recognition for innovative work in biopharmaceuticals and precision medicine.
2024 Second National Innovation Award - Startup Enterprise
Honored as a startup enterprise at the national level.
2024 21st National Innovation Award - Startup (Biopharmaceuticals and Precision Medicine)
Received the 21st National Innovation Award for achievements in biotech and personalized medicine.
Merck Collaboration on Bionic Lung Cancer Chip
Partnership with Merck to develop bionic lung cancer chips for personalized treatment.
Pythia Biotech's Lung Cancer Bionic Chip Mass Production
Advancement towards mass production of lung cancer chips to accelerate personalized medicine.